1
Smith Paul David: Combination 059. Astrazeneca, Astrazeneca, Smith Paul David, GLOBAL INTELLECTUAL PROPERTY, April 23, 2009: WO/2009/050506 (38 worldwide citation)

This invention relates to a combination product, as defined herein, comprising a MEK inhibitor and a mTOR-selective inhibitor, and to methods for the production of an anti-cancer effect in a patient, which is accordingly useful in the treatment of cancer in a patient. More 5 specifically the present ...


2
Paul David SMITH: Combination 059. Astrazeneca, Astrazeneca R&D Boston, April 16, 2009: US20090099174-A1

This invention relates to a combination product, as defined herein, comprising a MEK inhibitor and a mTOR-selective inhibitor, and to methods for the production of an anti-cancer effect in a patient, which is accordingly useful in the treatment of cancer in a patient. More specifically the present i ...


3
Smith Paul David: Combination 059. Astrazeneca, guan lixin li liantao, November 24, 2010: CN200880120865

This invention relates to a combination product, as defined herein, comprising a MEK inhibitor and a mTOR-selective inhibitor, and to methods for the production of an anti-cancer effect in a patient, which is accordingly useful in the treatment of cancer in a patient. More 5 specifically the present ...